Osilodrostat Effective for Patients With Cushing Disease
Investigators report outcomes from the LINC-4 study that evaluated outcomes following osilodrostat treatment for Cushing disease.
Cushing Syndrome
Hair Cortisol Measurement Not Effective for Identifying Autonomous Cortisol Secretion in Adrenal Incidentalomas
A team of investigators measured concentrations of 5 corticosteroid hormones in the keratin matrix of patients with adrenal incidentalomas with or without cortisol autonomy.
Cushing Syndrome May Be Predicted More Accurately With New Diagnostic Test
The complexity of Cushing syndrome often makes diagnosis difficult. Researchers sought to create a diagnostic tool that could determine which patients may be at risk for developing the disease.
Osilodrostat Improves Signs and Symptoms Associated With Cushing Disease
A team of investigators conducted a phase 3, multicenter study with a double-blind, randomized withdrawal period to assess the effects of twice-daily osilodrostat in patients with Cushing disease.
Genetic Basis for PMAH Enables Earlier Diagnosis, Improves Management of Cushing Syndrome
Several research studies presented at ENDO 2021 have evaluated the molecular mechanisms underlying Cushing syndrome to facilitate earlier diagnosis and improve disease management.
Osilodrostat Associated With Sustained Reduction of UFC in Cushing’s Disease
Osilodrostat treatment was found to be associated with a rapid and sustained reduction in mean concentration of urinary free cortisol and improved clinical symptoms in patients with Cushing’s disease.
Special Considerations for Patients With Cushing Syndrome and COVID-19
Patients with Cushing syndrome are at an increased risk for infections, including severe COVID-19, due to immunodeficiency and other comorbidities.
Osilodrostat Now Available for Treatment of Patients With Cushing Disease
Isturisa is exclusively available through the R.A.R.E.™ Patient Support Program and distributed via AnovoRx specialty pharmacy.
Novel Therapy for Cushing Disease Receives FDA Approval
The Food and Drug Administration (FDA) has approved Isturisa® (osilodrostat; Recordati) for the treatment of adults with Cushing disease for whom pituitary surgery is not an option or has not been curative.
No Clear Distinguishing Factors for Primary Aldosteronism Plus Subclinical Cushing Syndrome
No reference criteria can definitively distinguish patients with primary aldosteronism and subclinical Cushing syndrome from those with these conditions alone.
- Loading...
Loading...
Next post in Adrenal
Loading... 
Loading...